Morand et al Tyk2i deucravacitinib in SLE. 48-week phase 2 RCT. SRI(4) PBO: 34.4%; DEUC 3 mg BID: 58.2%, P =0.0006; DEUC 6 mg BID: 49.5%, P =0.021; DEUC 12 mg QD: 44.9%, P =0.078. BICLA, LLDAS, CLASI-50, active joint count also+ @RheumNow #EULAR2022 LB0004 https://t.co/MBPc9xQFvG https://t.co/n3GUwl0RtD

BE OPTIMAL Phase 3 RCT Bimekizumab dual IL17A & F inhibitor in bionaive PsA ⭐️ACR50 wk 16 43.9% vs 10% PBO ⭐️PASI 90 wk 16 61% vs. 3% PBO ⭐️separation from wk 4 Safety: fungal injections BKZ > ADA @RheumNow LB0001 #EULAR2022 https://t.co/7ZwV1XDSNb

PAISLEY LB004 @EricFMorand on deucravacitinib phase 2 for SLE ⭐️Meets primary endpt: SRI(4) ⭐️Secondary endpts: BICLA, LLD, CLASI, jt count, biomarkers improved ⭐️Safety data wo VTE, CVD events Earlier at #EULAR2022, BRAVE trial phase 3 baricitinib: No benefit in SLE @RheumNow https://t.co/3YpPSJcenF

Wetterslev et al showed that almost all of 108 axSpA patients in clinical remission flared during tapering,47% flared at 2/3 to ½ dose and 53% at 1/3 to discontinuation. Higher baseline physician global score was an independent predictor of flare #EULAR2022 @RheumNow POS0298 https://t.co/RELuiB3Enl

PAISLEY study Phase 2 RCT Deucravacitinib in SLE meets primary endpoint wk 32 Results for dose 3mg BID: *SRI(4) response 58.2% vs. PBO 34% *LLDAS 36% *CLASI 70% *⬇️ SJC No new safety signal Now waiting for Phase 3 👀 @RheumNow LB0004 #EULAR2022 #Lupus https://t.co/2KYSvfq4h7

Dr Coates @DrLauraCoates et al. Domains contributing to MDA achievement in guselkumab treated PsA. Physican assessed improved faster than patient assessed. Age, fatigue, BMI, baseline domain score determinants @RheumNow #EULAR2022 POS1067 https://t.co/vPsmeyPjzG

Talking about tapering studies in inflammatory arthritis, but true throughout all of rheumatology: Not all flares are equal. This area is full of nuance, we need to think more closely about how we study them. #EULAR2022 @RheumNow https://t.co/tzqqNZv5Ct

#POS1112 #EULAR2022 A crossover RCT assessed effect of weight- and non-weight bearing exercises on type 2 collagen in knee #osteoarthritis. Small rise in collagen turnover markers initially for 24hrs. Gradual rise later on was contributed to cardiovascular influence @RheumNow https://t.co/AOxdFNihPR

Shall we include US findings in CASPAR criteria? ⚡️ Adding US tenosynovitis and/or enthesitis - improves Specificity 91% vs. 68% -while maintaining sensitivity 92% vs. 96% #EULAR2022 @RheumNow POS0315 https://t.co/kuxPpVEQng

Dr Nash @drpnash Baseline determinants of pain response in IL23i guselkumab. Gus improved pain by week 2. Higher baseline pain, lower fatigue, lower TJC + predictors, NSAID use - predictor @RheumNow #EULAR2022 POS1070 https://t.co/4aNz9IQySj

The potential for patients to benefit from digital health technologies in rheumatology is multifaceted, upside might be enormous. There's so much space for us all, but there are factors in many domains where it can all go wrong. We need to raise standards. #EULAR2022 @RheumNow https://t.co/TozfK1Qs16

High markers at baseline of IL23 pathway better predict ACR20 response to #deucracitinib in #PsA #psoriatic arthritis. Analysis of RCT @eular_org @RheumNow #POS0005 Good proof of concept of TYK2 efficacy https://t.co/yyH5niUEEU